Reviewer's report

**Title:** T/L-type calcium channel blocker reduces composite ranking for relative risk according to new KDIGO guidelines in patients with chronic kidney disease

**Version:** 2 **Date:** 24 March 2013

**Reviewer:** Jicheng Lv

**Reviewer's report:**

The authors have answered nearly all my questions. But I am still concerned about GFR formular. I would suggest the authors do a sensitivity analysis based on the CKD-EPI formular.

**Level of interest:** An article whose findings are important to those with closely related research interests

**Quality of written English:** Acceptable

**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I have got hypertension research funds from Pfizer.